Marion BOSSY

Marion Bossy is an experienced leader with over 10 years of experience driving growth strategies and business turnarounds in the pharmaceutical and biotech sectors.
She advises senior executives on operational and financial performance improvement, including restructuring, organizational design, cost optimization, and analytics-enabled decision making.
A veterinarian by training, Marion Bossy is a recognized healthcare expert with deep specialization in R&D strategy, advanced analytics, and Real-World Evidence (RWE). She supports clients in leveraging real-world data to improve R&D productivity, accelerate development timelines, inform portfolio choices, and strengthen market access and lifecycle strategies.
Marion Bossy has supported biotechs and large pharmaceutical companies in scaling through organic and inorganic growth. Her work includes leading due diligences, shaping enterprise-wide strategies, designing analytics-enabled target operating models, and launching value-capture offices to deliver rapid impact.
Prior to joining FTI, Marion Bossy was an Associate Partner at McKinsey & Company, serving global biotech and pharmaceutical clients and co-leading the European R&D transformation service line. She also led global medical strategy at Sophia Genetics.
Marion holds a Doctorate in Veterinary Medicine and a Master of Science in Management, with a specialization in U.S. healthcare systems, and is a certified public health veterinarian. She has lived in France, Switzerland, the United States, and New Zealand, and has worked across Europe, North America, and Asia, including the UK, Canada, Spain, Belgium, Germany, Austria, and Japan.

Relevant Experience

Led Identification of novel indications for various immunology assets (either in development on already on market), leveraging RWE and Advanced analytics
Supported accelerations of development of immunology assets leveraging various analytical use cases (incl. subpopulation identification and synthetic control arm)
Led the re-design R&D organization of a major pharma player to allow for RWE to be included in key decision making
Co-led setting up the ACT-Accelerator during the Covid-19 pandemia to coordinate and accelerate pandemic response globally
Supported a leading veterinary chain with +150 clinics in revising its strategy, including footprint optimization and M&A roadmap
Supported re-shaping of the R&D organization for a global pharma player
Led launch strategy of various assets – immunology, oncology – incl. development strategy, market access mapping